SCHEMBL29882885

SCHEMBL29882885

Cc1ccc(F)c2c(=O)[nH]c(CCC(=O)N3CC=C(c4ccc(F)c(C#N)c4)CC3)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 4/20 0.43
▸ PARP2 Q9UGN5 1/20 0.43
▸ CCNT1 O60563 6/20 0.37
▸ CDK9 P50750 6/20 0.37
▸ S1PR1 P21453 1/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ KHK P50053 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ HSD17B10 Q99714 2/20 0.34
▸ USP2 O75604 2/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ NAMPT P43490 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23303629 1.00 PARP1 (0.43) PARP1PARP2CCNT1CDK9S1PR1
SCHEMBL23302430 0.94 PARP1 (0.43) PARP1PARP2CCNT1CDK9MAPK1
SCHEMBL29882179 0.94 PARP1 (0.43) PARP1PARP2CCNT1CDK9MAPK1
SCHEMBL23302546 0.89 PARP1 (0.54) PARP1PARP2CCNT1CDK9MAPK1
SCHEMBL23302480 0.88 PARP1 (0.43) PARP1PARP2CCNT1CDK9MAPK1
SCHEMBL29882367 0.87 PARP1 (0.46) PARP1PARP2CCNT1CDK9MAPK1
SCHEMBL23302471 0.87 PARP1 (0.46) PARP1PARP2CCNT1CDK9MAPK1
SCHEMBL29882413 0.86 PARP1 (0.38) PARP1PARP2CCNT1CDK9MAPK1
SCHEMBL23302605 0.86 PARP1 (0.38) PARP1PARP2CCNT1CDK9MAPK1
SCHEMBL23302807 0.85 PARP1 (0.44) PARP1PARP2CCNT1CDK9HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114929673-A Isoquinolinone derivatives, preparation method thereof, and pharmaceutical composition for preventing or treating poly (ADP-ribose) polymerase 1(PARP-1) -related diseases comprising the same as active ingredient 多临生物株式会社 2022-08-19 — — CN claimed
US-12459899-B2 Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient DIGMBIO, Inc. (KR) 2025-11-04 — — US disclosed
US-20230027362-A1 ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT DIGMBIO. INC. (KR) 2023-01-26 — — US disclosed
CN-114929673-A Isoquinolinone derivatives, preparation method thereof, and pharmaceutical composition for preventing or treating poly (ADP-ribose) polymerase 1(PARP-1) -related diseases comprising the same as active ingredient 多临生物株式会社 2022-08-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459899-B2 Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient PARP1, PARP2, PARP11 PARP1 1/4885PARP2 2/4885CCNT1 1628/4885
US-20230027362-A1 ISOQUINOLINONE DERIVATIVES, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING POLY(ADP-RIBOSE) POLYMERASE-1-RELATED DISEASES, COMPRISING THE SAME AS ACTIVE INGREDIENT PARP1, PARP2, PARP11 PARP1 1/4885PARP2 2/4885CCNT1 1628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback